Crossref

1. Genetic Heterogeneity, Therapeutic Hurdle Confronting Sorafenib and Immune Checkpoint Inhibitors in Hepatocellular Carcinoma

- Sara Atwa

- Margarete Odenthal

- Hend El Tayebi

2. Common ABCB1 polymorphisms in Greek patients with chronic hepatitis C infection: A comparison with hyperlipidemic patients and the general population

- Emma Gbandi

- Antonis Goulas

- Vassilios Sevastianos

- Stephanos Hadziyannis

- Athanasia Panderi

- John Koskinas

- George Papatheodoridis

- Themistoklis Vasiliadis

- Dimitrios Agapakis

- Andreas Protopapas

- Panagiota Ioannidou

- George Zacharakis

- Emmanuil Sinakos

- Sotiris Koutsounas

- Georgios Germanidis

3. The ABCB1-C3435T polymorphism likely acts as a risk factor for resistance to antiepileptic drugs

- Minzhi Li

- Jinjing Tan

- Xiaoqing Yang

- Li Su

- Juanjuan Xie

- Baoyun Liang

- Jianxiong Long

- Haiyun Jiang

- Qiugui Wei

- Tingting Shen

- Qing Chen

- Yan Yan

- Guangliang Wu

- Lian Gu

4. Correlation between clinical response to sorafenib in hepatocellular carcinoma treatment and polymorphisms of P-glycoprotein (ABCB1) and of breast cancer resistance protein (ABCG2): monocentric study

- Mahamadou Tandia

- Asma Mhiri

- Bernard Paule

- Raphaël Saffroy

- Valérie Cailliez

- Gaëlle Noé

- Robert Farinotti

- Laurence Bonhomme-Faivre